Skip to main content
TVPills

Keytruda Alternatives

Drugs like Keytruda (pembrolizumab) — other oncology medications advertised on TV that may be alternatives. Informational only — not medical advice. Only your doctor can decide what's right for you.

Unverified catalogue summary (alternative grouping) for Keytruda in US; not checked against current local product information.

Share

Opdivo

nivolumab · Bristol-Myers Squibb

Treats Multiple cancers

Unverified catalogue summary (alternative identity, manufacturer and indication) for Opdivo in US; not checked against current local product information.

Details vs Keytruda Cost

Xtandi

enzalutamide · Astellas Pharma US, Inc.

Treats Prostate cancer

Unverified catalogue summary (alternative identity, manufacturer and indication) for Xtandi in US; not checked against current local product information.

Details vs Keytruda Cost

Verzenio

abemaciclib · Eli Lilly

Treats HR+/HER2- breast cancer

Unverified catalogue summary (alternative identity, manufacturer and indication) for Verzenio in US; not checked against current local product information.

Details vs Keytruda Cost

Ibrance

palbociclib · Pfizer Laboratories (US labeler)

Treats HR-positive advanced or metastatic breast cancer, in specified HER2-negative and HER2-positive combination regimens

Unverified catalogue summary (alternative identity, manufacturer and indication) for Ibrance in US; not checked against current local product information.

Details vs Keytruda Cost

Kisqali

ribociclib · Novartis

Treats HR-positive, HER2-negative breast cancer

Unverified catalogue summary (alternative identity, manufacturer and indication) for Kisqali in US; not checked against current local product information.

Details vs Keytruda Cost

Lynparza

olaparib · AstraZeneca

Treats Ovarian, breast, prostate, and pancreatic cancers

Unverified catalogue summary (alternative identity, manufacturer and indication) for Lynparza in US; not checked against current local product information.

Details vs Keytruda Cost

Tagrisso

osimertinib · AstraZeneca

Treats EGFR mutation-positive non-small cell lung cancer

Unverified catalogue summary (alternative identity, manufacturer and indication) for Tagrisso in US; not checked against current local product information.

Details vs Keytruda Cost

Calquence

acalabrutinib · AstraZeneca

Treats Chronic lymphocytic leukemia and mantle cell lymphoma

Unverified catalogue summary (alternative identity, manufacturer and indication) for Calquence in US; not checked against current local product information.

Details vs Keytruda Cost

Imbruvica

ibrutinib · Pharmacyclics LLC / Janssen Biotech, Inc.

Treats Chronic lymphocytic leukemia and other blood cancers

Unverified catalogue summary (alternative identity, manufacturer and indication) for Imbruvica in US; not checked against current local product information.

Details vs Keytruda Cost

Jakafi

ruxolitinib · Incyte

Treats Myelofibrosis and polycythemia vera

Unverified catalogue summary (alternative identity, manufacturer and indication) for Jakafi in US; not checked against current local product information.

Details Cost

Nubeqa

darolutamide · Orion Corporation / Bayer HealthCare Pharmaceuticals Inc.

Treats Prostate cancer

Unverified catalogue summary (alternative identity, manufacturer and indication) for Nubeqa in US; not checked against current local product information.

Details Cost

Erleada

apalutamide · Janssen

Treats Prostate cancer

Unverified catalogue summary (alternative identity, manufacturer and indication) for Erleada in US; not checked against current local product information.

Details Cost
See all Oncology medications

Sources and editorial standards

Product-label references, not clinical verification. Medicine identification—not prescribing guidance. This page does not provide a complete safety or dosing reference. Check the official label for your country and exact product, and consult your pharmacist or prescriber before starting, stopping or changing treatment. Missing information does not mean a medicine is safe for you. Reference formulation scope (not dosing instructions): pembrolizumab intravenous solution 100 mg/4 mL (25 mg/mL) single-dose vial; excludes Keytruda Qlex combination injection

Unresolved / not established by these sources:

  • Clinical summaries, safety tiers and dosing guidance are withheld while their review remains unfinished.
  • A linked document may have been superseded. Confirm country, product, formulation and latest revision with the regulator or pharmacist.

Lookup resources (not product-specific citations; confirm formulation and country before use):

Frequently asked questions

What drugs are similar to Keytruda?

Unverified catalogue grouping, not a clinically established substitute or a checked local indication. Drugs like Keytruda include other oncology medications advertised on TV such as Opdivo, Xtandi, Verzenio and more. This is an editorial catalogue grouping, not a verified comparison of indications, safety or suitable substitutes. Ask your prescriber about treatment choices.

What can I take instead of Keytruda?

Unverified catalogue grouping, not a clinically established substitute or a checked local indication. Other oncology medications advertised on TV include Opdivo, Xtandi, Verzenio and others. The right alternative depends on your diagnosis, medical history and insurance — only your doctor can recommend a substitute for Keytruda. This page is informational only.

Is there a generic version of Keytruda?

Unverified catalogue grouping, not a clinically established substitute or a checked local indication. Keytruda is sold as pembrolizumab. Whether a lower-cost generic is available depends on patent status — ask your pharmacist, and see the cost & savings page for ways to pay less.

Are these alternatives the same as Keytruda?

Unverified catalogue grouping, not a clinically established substitute or a checked local indication. This catalogue grouping does not establish therapeutic equivalence, shared approved indications or suitability as a substitute. Do not switch medicines based on it; consult your prescriber.